Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.

In addition, Elevidys’s indication for non-patients has been removed, and the gene is now indicated only to treat ambulatory patients four years of age and older with Duchenne muscular dystrophy.

Here’s what you missed this week on Managed Healthcare Executive.

Healthcare is treated as an investment good in Spain in contrast to the American framing, which treats healthcare as a consumer good.

High levels of integrin beta-6 (IB6) in metastatic non-small cell lung cancer suggest that it could be a target for treatment.

The investigational lenacapavir-bictegravir tablet has the potential to reduce the pill burden of HIV treatment, according to a recent news release.

The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings.

mRNA COVID-19 vaccines enhance immune responses, improving cancer treatment outcomes with immune checkpoint inhibitors and offering hope for hard-to-treat tumors.